Please login to order a test.
BRAF is an important member of the mitogen-activated protein kinase (MAPK) pathway that influences cell proliferation. This test will detect all V600 mutations of the BRAF oncogene frequently found in human cancers, such as melanoma, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, and hairy cell leukemia, allowing the determination of drug response, aiding the diagnosis and providing prognosis information. More than 90% of mutations are the V600E (c1799T>A) mutation, but other V600 mutations have been reported.
This test can detect the following BRAF V600 mutations: V600E, V600E2, V600K, V600D, V600R, V600A, V600G, V600M, V600L.
This assay is able to detect 5% mutation in a background of wild-type DNA. This assay does not distinguish between the V600E, V600D and V600E2 mutations.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
SNaPshot Multiplex PCR (primer extension-based method)
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks or slides, thyroid fine needle aspirate (FNA), whole blood, or bone marrow
FFPE tissue block or four unstained slides and one matching H&E-stained slide at 5 μM; 5 to 10 mL FNA in RPMI or CytoLyt container; 3 to 5 mL whole blood, 1 to 2 mL bone marrow
Two unstained slides and one matching H&E-stained slide at 5 μM. Samples with >4mm² and ≥50% tumor content are preferred; FNA (with sufficient cells for DNA extraction); 3 mL blood, 1 mL bone marrow
Ship at room temperature. If whole blood, bone marrow, or FNA in RPMI specimens are to be stored prior to shipment at 2°C to 8°C. Store FFPE block or slides, FNA in CytoLyt container at room temperature.
Causes for Rejection
Tumor block containing no tumor; broken or stained slides; clotted or frozen whole blood or bone marrow
Please provide a copy of the pathology report. Direct any questions regarding this test to customer service at 800-345-4363. BRAF testing will be delayed if the pathology report is not received.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|481030||BRAF Gene Mutation Analysis||481031||Results:||58483-9|
|481030||BRAF Gene Mutation Analysis||481032||Indications:||42349-1|
|481030||BRAF Gene Mutation Analysis||481033||Specimen Location:||N/A|
|481030||BRAF Gene Mutation Analysis||481034||Specimen Type:||31208-2|
|481030||BRAF Gene Mutation Analysis||481035||Block #:||N/A|
|481030||BRAF Gene Mutation Analysis||481076||Nucleotide Change:||48004-6|
|481030||BRAF Gene Mutation Analysis||481079||Amino Acid Change:||48005-3|
|481030||BRAF Gene Mutation Analysis||481521||Background:||77202-0|
|481030||BRAF Gene Mutation Analysis||481749||Methodology:||49549-9|
|481030||BRAF Gene Mutation Analysis||481059||References:||75608-0|
|481030||BRAF Gene Mutation Analysis||481081||Director Review:||72486-4|
|481030||BRAF Gene Mutation Analysis||480903||Microdissection Performed||8100-0|
|481030||BRAF Gene Mutation Analysis||481181||Referring Physician||18781-5|
|481030||BRAF Gene Mutation Analysis||481182||Treating Physician||N/A|
|481030||BRAF Gene Mutation Analysis||481183||Body Site||39111-0|
|481030||BRAF Gene Mutation Analysis||481168||Client Specimen ID||N/A|
|481030||BRAF Gene Mutation Analysis||481172||Specimens Received||N/A|
|481030||BRAF Gene Mutation Analysis||481173||Clinical Data||55752-0|
|481030||BRAF Gene Mutation Analysis||481175||Interpretation||51968-6|
|481030||BRAF Gene Mutation Analysis||481176||Analytical Results||53844-7|
|481030||BRAF Gene Mutation Analysis||481177||Comments||77202-0|
|481030||BRAF Gene Mutation Analysis||481178||Signed By||19139-5|
|481030||BRAF Gene Mutation Analysis||481179||Disclaimers||N/A|
|481030||BRAF Gene Mutation Analysis||481180||51969-4|